By demonstrating the efficiency of our newly-designed PROTACs on the degradation of C-TDP-43 aggregates and oligomers, we wish to develop these small molecules as new drugs against misfolding proteins in neurodegenerative diseases. Here, TARDBP is linked to neurodegenerative disease.